Published in Atherosclerosis on August 01, 1991
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ (2000) 1.80
Detection of bacteraemia in patients with fever and neutropenia using 16S rRNA gene amplification by polymerase chain reaction. Eur J Clin Microbiol Infect Dis (1998) 1.78
Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci U S A (1992) 1.35
The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut (1998) 1.25
Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc (2013) 1.20
Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol (2008) 1.07
Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol (2011) 1.04
Familial hypercholesterolaemia commonly presents with Achilles tenosynovitis. Ann Rheum Dis (2005) 0.94
A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest (1997) 0.93
Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature. Arthritis Res Ther (2013) 0.85
Six DNA polymorphisms in the low density lipoprotein receptor gene: their genetic relationship and an example of their use for identifying affected relatives of patients with familial hypercholesterolaemia. J Med Genet (1993) 0.75
Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol (1987) 9.10
Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol (2001) 8.88
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest (1998) 6.76
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol (1998) 5.93
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. Br Med J (Clin Res Ed) (1987) 5.01
Cancer linked to Alzheimer disease but not vascular dementia. Neurology (2009) 4.83
DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet (1998) 4.53
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Hippocampal morphometry in schizophrenia by high dimensional brain mapping. Proc Natl Acad Sci U S A (1998) 3.72
The AD8: a brief informant interview to detect dementia. Neurology (2005) 3.65
Assessing family sharing of diabetes responsibilities. J Pediatr Psychol (1990) 3.43
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med (1989) 3.32
Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. Neuroimage (2005) 3.21
Celecoxib--is it worth celebrating? S Afr Med J (2000) 3.01
Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet (1981) 2.95
Beta-blockers for hypertension. Cochrane Database Syst Rev (2007) 2.91
Normal brain in human newborns: apparent diffusion coefficient and diffusion anisotropy measured by using diffusion tensor MR imaging. Radiology (1998) 2.81
Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet (1999) 2.75
Cloning of the afl-2 gene involved in aflatoxin biosynthesis from Aspergillus flavus. Appl Environ Microbiol (1993) 2.71
A cladistic analysis of phenotype associations with haplotypes inferred from restriction endonuclease mapping. II. The analysis of natural populations. Genetics (1988) 2.68
Cloning of the Aspergillus parasiticus apa-2 gene associated with the regulation of aflatoxin biosynthesis. Appl Environ Microbiol (1993) 2.57
Molecular characterization of aflR, a regulatory locus for aflatoxin biosynthesis. Appl Environ Microbiol (1994) 2.56
Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A (1991) 2.53
Reliability of the Washington University Clinical Dementia Rating. Arch Neurol (1988) 2.48
The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation (1984) 2.45
The prevalence and correlates of fear of falling in elderly persons living in the community. Am J Public Health (1994) 2.37
Comparative mapping of aflatoxin pathway gene clusters in Aspergillus parasiticus and Aspergillus flavus. Appl Environ Microbiol (1995) 2.33
Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Dementia of the Alzheimer type. Neurology (2000) 2.31
Hyperlipidaemia, hypertension, and coronary heart disease. Lancet (1995) 2.28
Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet (1999) 2.27
Identification of O-methylsterigmatocystin as an aflatoxin B1 and G1 precursor in Aspergillus parasiticus. Appl Environ Microbiol (1987) 2.24
Improved evaluation of the location and mechanism of mitral valve regurgitation with a systematic transesophageal echocardiography examination. Anesth Analg (1999) 2.23
A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol (1998) 2.22
Cloning and characterization of a cDNA from Aspergillus parasiticus encoding an O-methyltransferase involved in aflatoxin biosynthesis. Appl Environ Microbiol (1993) 2.10
Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation (1999) 2.08
Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve (1983) 1.99
The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem (1993) 1.94
ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol (2000) 1.92
Very Early Constraint-Induced Movement during Stroke Rehabilitation (VECTORS): A single-center RCT. Neurology (2009) 1.87
Kinetic studies of gene frequency. I. Use of a DNA copy of reticulocyte 9 S RNA to estimate globin gene dosage in mouse tissues. J Mol Biol (1974) 1.87
A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia (2012) 1.83
Broadband neural encoding in the cricket cercal sensory system enhanced by stochastic resonance. Nature (1996) 1.80
The stomatogastric nervous system: structure and function of a small neural network. Prog Neurobiol (1976) 1.80
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ (2000) 1.80
The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann N Y Acad Sci (1977) 1.79
Appearance of enzyme activities catalyzing conversion of sterigmatocystin to aflatoxin B1 in late-growth-phase Aspergillus parasiticus cultures. Appl Environ Microbiol (1987) 1.79
Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol (1991) 1.78
Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 1.78
Kinetic studies of gene frequency. II. Complexity of globin complementary DNA and its hybridization characteristics. J Mol Biol (1974) 1.78
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet (2006) 1.76
Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med (2010) 1.76
Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months) Neurology (1993) 1.75
Pretreatment blood pressure as a predictor of 21-year mortality. Am J Hypertens (2000) 1.75
Mouse globin gene expression in erythroid and non-erythroid tissues. Cell (1976) 1.75
Wrong lesson from Finnish trial of cardiovascular disease prevention. Lancet (1992) 1.74
A randomized clinical trial of continuous-flow nitrous oxide and midazolam for sedation of young children during laceration repair. Ann Emerg Med (2001) 1.74
Interlaboratory histopathologic assessment of Alzheimer neuropathology: different methodologies yield comparable diagnostic results. Alzheimer Dis Assoc Disord (1993) 1.72
Translation of mouse globin messenger ribonucleic acid from which the poly(adenylic acid) sequence has been removed. Biochemistry (1974) 1.72
Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's muscular dystrophy. Phys Ther (1992) 1.67
Rapid killing of single neurons by irradiation of intracellularly injected dye. Science (1979) 1.67
Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet (2001) 1.67
Temporal encoding in nervous systems: a rigorous definition. J Comput Neurosci (1995) 1.67
Increased expression of Aspergillus parasiticus aflR, encoding a sequence-specific DNA-binding protein, relieves nitrate inhibition of aflatoxin biosynthesis. Appl Environ Microbiol (1995) 1.66
Human angiotensin I-converting enzyme gene and endurance performance. J Appl Physiol (1985) (1999) 1.61
Relapse of duodenal ulcer: does it matter which drug is used in initial treatment? Br Med J (Clin Res Ed) (1986) 1.60
Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies. Pediatrics (1998) 1.60
Accuracy of predonation Hct sampling affects donor safety, eligibility, and deferral rates. Transfusion (2001) 1.60
Alzheimer disease and cancer. Neurology (2005) 1.60
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis (1991) 1.59
Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension (1995) 1.58
The transient respiratory effects in man of sudden changes in alveolar CO2 in hypoxia and in high oxygen. Respir Physiol (1974) 1.58
A combined hospital experience with fundoplication and gastric emptying procedure for gastroesophageal reflux in children. J Am Coll Surg (1995) 1.57
Apolipoprotein E genotype: epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease: the Copenhagen City Heart Study. J Am Coll Cardiol (2000) 1.57
Allele specific amplification by tetra-primer PCR. Nucleic Acids Res (1992) 1.56
Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis (2005) 1.55
Analogs of cyclic AMP that elicit the biochemically defined conformational change in catabolite gene activator protein (CAP) but do not stimulate binding to DNA. J Mol Biol (1985) 1.55
Antacid maintenance therapy in the prevention of duodenal ulcer relapse. Gut (1988) 1.54
Chronic progressive renal disease: rate of change of serum creatinine concentration. Kidney Int (1977) 1.52
Purification of a 40-kilodalton methyltransferase active in the aflatoxin biosynthetic pathway. Appl Environ Microbiol (1993) 1.52
Trichobezoar obstructing the terminal ileum. Trop Doct (2002) 1.51
Averufanin is an aflatoxin B1 precursor between averantin and averufin in the biosynthetic pathway. Appl Environ Microbiol (1987) 1.49
Haemochromatosis genotype and iron overload: association with hypertension and left ventricular hypertrophy. J Intern Med (2010) 1.49
Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation (1997) 1.48
Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment. Ann Neurol (1988) 1.48
A controlled clinical trial of local anesthesia for lumbar punctures in newborns. Pediatrics (1991) 1.47
Falls in the elderly: reliability of a classification system. J Am Geriatr Soc (1991) 1.46
The Aspergillus parasiticus polyketide synthase gene pksA, a homolog of Aspergillus nidulans wA, is required for aflatoxin B1 biosynthesis. Mol Gen Genet (1995) 1.46
Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels. J Intern Med (2011) 1.46
A comparison of two computer-administered versions of the NIMH Diagnostic Interview Schedule. J Psychiatr Res (1992) 1.45
The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo. Br J Cancer (1998) 1.44
Family characteristics of diabetic adolescents: relationship to metabolic control. Diabetes Care (1982) 1.43
The differential ferrioxamine test in the management of idiopathic haemochromatosis. Lancet (1969) 1.43
Use of a modified shell vial technique to quantitate cytomegalovirus viremia in a population of solid-organ transplant recipients. J Clin Microbiol (1992) 1.43
Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet (1988) 1.42
Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology (1991) 1.40
Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. J Clin Endocrinol Metab (1996) 1.39